Full Press Release Details
Bagsværd, Denmark, 12 May 2026— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Caroline Munk Esbjerg | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument,type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Shares received as gift | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.30 | 50 | |||||
| d) | Aggregated informationAggregated volumePrice | 50 sharesDKK 14,715 | ||||
| e) | Date of the transaction | 2026-05-07 | ||||
| f) | Place of the transaction | Outside a trading venue |
• Aggregated volume
• Price
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
| a) | Name of the Board member/Executive/Associated Person | Sofie Munk Esbjerg | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Closely associated person to Karsten Munk Knudsen, Executive Vice President, Chief Financial Officer (CFO) | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3 | Details of the issuer | |||||
| a) | Name | Novo Nordisk A/S | ||||
| b) | LEI | 549300DAQ1CVT6CXN342 | ||||
| 4 | Details of the transaction(s) | |||||
| a) | Description of the financial instrument,type of instrument, | Shares | ||||
| Identification code | Novo Nordisk B DK0062498333 | |||||
| b) | Nature of the transaction | Shares received as gift | ||||
| c) | Price(s) and volume(s) | Price(s) | Volume(s) | |||
| DKK 294.25 | 50 | |||||
| d) | Aggregated informationAggregated volumePrice | 50 sharesDKK 14,712.50 | ||||
| e) | Date of the transaction | 2026-05-07 | ||||
| f) | Place of the transaction | Outside a trading venue |
• Aggregated volume
• Price
About Novo NordiskNovo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. For more information, visitnovonordisk.com,Facebook,Instagram,X,LinkedInandYouTube
Contacts for further information
| Media: | |
| Ambre James-Brown+45 3079 9289abmo@novonordisk.com | Liz Skrbkova(US)+1 609 917 0632lzsk@novonordisk.com |
| Investors: | |
| Michael Novod+45 3075 6050nvno@novonordisk.com | Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com |
| Max Ung+45 3077 6414mxun@novonordisk.com | Sina Meyer+45 3079 6656azey@novonordisk.com |
| Alex Bruce+45 3444 2613axeu@novonordisk.com | Christoffer Sho Togo Tullin+45 3079 1471cftu@novonordisk.com |
| Mads Berner Bruun+45 3075 2936mbbz@novonordisk.com | Frederik Taylor Pitter+1 609 613 0568fptr@novonordisk.com |
Company announcement No 31 / 2026
Attachment
• CA260512-insider-trading